| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,956 |
5,075 |
$454K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,093 |
3,519 |
$198K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,210 |
964 |
$93K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
500 |
455 |
$71K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
557 |
481 |
$42K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
526 |
434 |
$36K |
| 96127 |
|
1,511 |
1,292 |
$30K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
280 |
241 |
$24K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
696 |
648 |
$16K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
389 |
260 |
$14K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
792 |
680 |
$13K |
| D1206 |
Topical application of fluoride varnish |
316 |
278 |
$8K |
| 96160 |
|
560 |
409 |
$8K |
| 92551 |
|
439 |
350 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
201 |
113 |
$4K |
| 90686 |
|
364 |
325 |
$4K |
| 90698 |
|
198 |
172 |
$2K |
| 83655 |
|
157 |
121 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
71 |
69 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
32 |
25 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
99 |
92 |
$2K |
| 90670 |
|
141 |
134 |
$2K |
| 90674 |
|
84 |
76 |
$1K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
31 |
30 |
$1K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
27 |
13 |
$1K |
| 85018 |
|
427 |
349 |
$990.64 |
| 83718 |
|
95 |
79 |
$726.10 |
| 99173 |
|
95 |
71 |
$703.89 |
| 36416 |
|
121 |
99 |
$496.10 |
| 90661 |
|
28 |
27 |
$467.88 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
29 |
25 |
$438.00 |
| 82465 |
|
95 |
80 |
$402.80 |
| 99174 |
|
49 |
36 |
$365.05 |
| 90734 |
|
31 |
25 |
$325.35 |
| 90633 |
|
28 |
27 |
$269.72 |
| 90716 |
|
14 |
13 |
$244.50 |
| 90651 |
|
12 |
12 |
$200.52 |
| 90707 |
|
14 |
13 |
$190.24 |
| 90700 |
|
15 |
13 |
$188.40 |
| 90744 |
|
16 |
12 |
$146.66 |